If you would like to receive Vaxin News please click the following email link with Vaxin News in the subject line.
vaxinnews@vaxin.com

HERBERT L. HEYNEKER, PH.D., TO JOIN VAXIN’S BOARD OF DIRECTORS - May 4, 2010
Press Release

VAXIN RECEIVES BIRMINGHAM BUSINESS JOURNAL’S “PACESETTER” AWARD - April 27, 2010
Press Release

VAXIN CEO CREDITS FLU SCARE FOR ’09 GROWTH - April 22, 2010
Birmingham Business Journal

BIRMINGHAM BIOTECH FIRM VAXIN ADDS HEAVY INDUSTRY HITTERS TO BOARD - February 19, 2010
Birmingham Business Journal

VAXIN ANNOUNCES APPOINTMENTS TO BOARD OF DIRECTORS - February 19, 2010
Press Release

VAXIN DEAL MAY SIGNAL MATURATION OF BIRMINGHAM BIOTECH INDUSTRY - October 23, 2009
Birmingham Business Journal

VAXIN LAUNCHES JOINT VENTURE WITH ANC BIO IN KOREA- October 14, 2009
Press Release

VAXIN PANDEMIC VACCINE PHASE I RELEASE- July 17, 2009
Press Release

VAXIN TECH 50 RELEASE- June 15, 2009
Press Release

WHAT'S ON THE HORIZON FOR A SWINE FLU VACCINE - May 6, 2009
getbetterhealth.com

VAXIN COMPLETES DOSING OF PHASE 1 HUMAN STUDY OF H5N1 PANDEMIC FLU VACCINE- February 24, 2009
Press Release

VAXIN RECEIVES $1.4 MILLION FOR ANTHRAX VACCINE DEVELOPMENT- December 10, 2008
Press Release

VAXIN AND CRUCELL ANNOUNCE COLLABORATION TO FIGHT ALZHEIMER’S DISEASE- November 13, 2008
Press Release

VAXIN TO PRESENT AT THE RODMAN & RENSHAW 1OTH ANNUAL HEALTHCARE CONFERENCE - November 5, 2008
Press Release

Vaxin begins pandemic flu study using Birmingham volunteers - October 8, 2008
The Birmingham News

VAXIN INITIATES PHASE I HUMAN STUDY OF H5N1 PANDEMIC FLU VACCINE - October 8, 2008
Press Release

VAXIN RECEIVES $100,000 GRANT FOR DEVELOPMENT OF ACNE VACCINE- September 18, 2008
Press Release

VAXIN AWARDED NIH FUNDING FOR AVIAN FLU VACCINE DEVELOPMENT- September 10, 2008 Press Release

Vaxin developing game-changing flu vaccine - August 26, 2008
TechJournal South

VAXIN’S PANDEMIC VACCINE SPOTLIGHTED- August 13, 2008
Promising data presented at Immunotherapeutics & Vaccine Summit
Press Release

Vaxin Welcomes New CEO - August 8, 2008
New Leader To Advance Company’s Product Pipeline Into Clinical Development
Press Release

Biotech firm Vaxin taps new CEO, looks for VC funds - August 8, 2008
Birmingham Business Journal

E. coli-Vectored Tetanus and Anthrax Vaccine Patch Protective in Mice - July 4, 2006
Link to article

Vaxin executives eye Taiwan for money, location incentives - February 17, 2006
Link to article

(Taiwan) Vaxin's approach a 'new vision' for the vaccine industry: CEO (Taiwan Life Sciences Weekly - January 16, 2006
Link to article

Vaxin’s technology at the forefront of national development trends for 2004 - January 11, 2005
Link to article

New targets for anthrax remedies (SeparationsNOW.com)-December 2004
Link to article

Federal Funding is Key to vaccine producer Vaxin (Birmingham Business Journal) -Oct. 22, 2004
Link to article

Data from Vaxin’s First Flu Vaccine Clinical Trial Reported in Journal “Vaccine” -Jan. 11, 2005
Birmingham, AL – January 11, 2005 – Vaxin Inc., a privately-held biotechnology company, has demonstrated, in a Phase I human clinical study, that the company’s recombinant influenza vaccine provides a potential alternative to traditional flu vaccines. Published in the January 11, 2005 issue of the journal Vaccine (volume 23, issue 8, pages 1029-1036), the paper is entitled “Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.” The authors conclude that Vaxin’s novel flu vaccine, which is produced in cell culture, was immunogenic and well tolerated by human volunteers.
Link to whole article

Revolutionary Flu Vaccine in Development by Vaxin Inc.-Oct. 11, 2004
Birmingham, AL – October 11, 2004 – In the midst of mounting concerns about shortages of flu vaccine supplies and worries about the deadly avian flu virus and its potential to cause a pandemic, Vaxin Inc., a privately-held biotechnology company in Birmingham, Alabama, is quietly developing a revolutionary new flu vaccine. The Vaxin influenza vaccine differs from traditional flu vaccines in two important ways: its method of manufacture and its method of delivery; both of which convey potentially significant advantages over traditional flu vaccines.
Link to whole article

Crucell And Vaxin Announce PER.C6 Licensing Agreement-Sept. 13, 2004
Birmingham, AL – Sept. 13, 2004 – Vaxin Inc., an emerging biotechnology company developing new vaccines for influenza, anthrax, respiratory syncytial virus (RSV) and other diseases, announced today that it has entered into a license agreement with Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL). This non-exclusive license agreement allows Vaxin to use Crucell’s PER.C6® cell line for the development, manufacture and commercialization of its recombinant adenoviral vaccines against certain respiratory viruses.
Link to whole article

Crucell Announces PER.C6(R) Licensing Agreement with Vaxin for Adenoviral Vaccine-Sept. 13, 2004
Leiden, The Netherlands, September 13, 2004 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has signed a non-exclusive PER.C6® technology license agreement with Vaxin, Inc. of Birmingham, Alabama. This license agreement allows Vaxin to use PER.C6® technology for research, development and commercialization of recombinant adenoviral vaccines against certain respiratory viruses.
Link to whole article